BMAL1 and acute lymphoblastic leukemia: To address this hypothesis, SUP-T1 and RPMI-8402 human T-ALL cell lines were treated for three days with SR9011, a specific agonist of the nuclear hormone receptors Rev-Erbα and Rev-Erbβ,which inhibit BMAL1 transcription [28, 29].